[1] [17] For instance, in pivotal trials of semaglutide for diabetes, headache was reported by approximately 6-8% of participants receiving the medication compared to 5-6% in placebo groups, suggesting a modest but measurable association
For appropriate patients, it may be part of a personalized treatment plan guided by a licensed clinician
Instead, companies are using compounding pharmacies to bypass the FDA-approved manufacturers and generate profit
Furthermore, a multinational cohort study involving five countries revealed that neither insulin detemir nor insulin glargine significantly increases cancer risk compared to human insulin [107]
In addition to better blood sugar management, GLP-1 medications often facilitate weight loss and can provide cardiovascular protective benefits for patients with a history of heart disease
These discrepancies may be due to different diagnostic criteria and evaluation methods used across studies [18]